|
KMID : 1146120170030010009
|
|
Journal of Mucopolysaccharidosis and Rare Diseases
2017 Volume.3 No. 1 p.9 ~ p.13
|
|
|
Newborn Screening of Lysosomal Storage Diseases, Including Mucopolysaccharidoses
|
|
Kim Su-Jin
|
|
|
Abstract
|
|
|
|
Tandem mass spectrometry and other new technologies for the multiplex and quantitative analysis of dried blood spots have emerged as powerful techniques for the early screening and assessment of newborns for lysosomal storage diseases (LSDs). Screening newborns for these diseases is important, since treatment options, including enzyme replacement therapy or hematopoietic transplantation, are available for some LSDs, such as infant-onset Pompe disease, Fabry disease, some types of mucopolysaccharidoses (MPSs), and Krabbe disease. For these diseases, early initiation of treatment, before symptoms worsen, often leads to better clinical outcomes. Several problems, however, are associated with newborn screening for LSDs, including the development of accurate test methods to reduce low false-positive rates and treatment guidelines for late-onset or mild disease variants, the high costs associated with multiplex assays, and ethical issues. In this review, we discuss the history, current status, and ethical problems associated with the newborn screening for LSDs, including MPSs.
|
|
|
KEYWORD
|
|
|
Newborn screening, Lysosomal storage disease, Mucopolysacchariodis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|